Long‐Term Trends of HIV Type 1 Drug Resistance Prevalence among Antiretroviral Treatment–Experienced Patients in Switzerland | Zendy

Viktor von Wyl | Zendy; Sabine Yerly | Zendy; Jürg Böni | Zendy; Philippe Bürgisser | Zendy; Thomas Klimkait | Zendy; Manuel Battegay | Zendy; Enos Bernasconi | Zendy; Matthias Cavassini | Zendy; Hansjakob Furrer | Zendy; Bernard Hirschel | Zendy; Pietro Vernazza | Zendy; P Francioli | Zendy; Sebastian Bonhoeffer | Zendy; Bruno Ledergerber | Zendy; Huldrych F. Günthard | Zendy

Open Access

Long‐Term Trends of HIV Type 1 Drug Resistance Prevalence among Antiretroviral Treatment–Experienced Patients in Switzerland

Author(s) -

Viktor von Wyl,

Sabine Yerly,

Jürg Böni,

Philippe Bürgisser,

Thomas Klimkait,

Manuel Battegay,

Enos Bernasconi,

Matthias Cavassini,

Hansjakob Furrer,

Bernard Hirschel,

Pietro Vernazza,

P Francioli,

Sebastian Bonhoeffer,

Bruno Ledergerber,

Huldrych F. Günthard

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/597352

Subject(s) - medicine , drug resistance , human immunodeficiency virus (hiv) , antiretroviral drug , hiv drug resistance , drug , term (time) , antiretroviral therapy , sida , virology , pediatrics , intensive care medicine , viral disease , viral load , pharmacology , microbiology and biotechnology , biology , physics , quantum mechanics

Accurate quantification of the prevalence of human immunodeficiency virus type 1 (HIV-1) drug resistance in patients who are receiving antiretroviral therapy (ART) is difficult, and results from previous studies vary. We attempted to assess the prevalence and dynamics of resistance in a highly representative patient cohort from Switzerland.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research